Administration of Traditional Chinese Blood Circulation Activating Drugs for Microvascular Complications in Patients with Type 2 Diabetes Mellitus

Journal of Diabetes Research

Volumn 2016, Issue , 2016, Pages

  He, Lisha ^a   Wang, Han ^a   Gu, Chengjuan ^a   He, Xinhui ^b   Zhao, Linhua ^a   Tong, Xiaolin ^a  

^a INSTITUTE OF CHINESE MATERIA MEDICA   (China)

^b BEIJING UNIVERSITY OF CHINESE MEDICINE   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ADVANCED GLYCATION END PRODUCT; CHINESE DRUG;

BLOOD RHEOLOGY; CHINESE MEDICINE; CIRCULATION; CLINICAL PRACTICE; DIABETIC MICROANGIOPATHY; DIABETIC NEPHROPATHY; DIABETIC PATIENT; DIABETIC RETINOPATHY; HEMOSTASIS; HUMAN; LIPID BLOOD LEVEL; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OXIDATIVE STRESS; PERIPHERAL NEUROPATHY; REVIEW; THROMBOCYTE AGGREGATION INHIBITION; VASCULAR DISEASE; VASCULAR ENDOTHELIUM; COMPLICATION; DIABETIC ANGIOPATHIES; DIABETIC NEPHROPATHIES; DIABETIC NEUROPATHIES; DRUG EFFECTS; THROMBOCYTE AGGREGATION; TREATMENT OUTCOME;

DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; DIABETIC NEPHROPATHIES; DIABETIC NEUROPATHIES; HUMANS; MEDICINE, CHINESE TRADITIONAL; OXIDATIVE STRESS; PLATELET AGGREGATION; TREATMENT OUTCOME;

EID: 84994669174     PISSN: 23146745     EISSN: 23146753     Source Type: Journal    
DOI: 10.1155/2016/1081657     Document Type: Review

References (114)

1. International Diabetes Federation, IDF Diabetes Altas Globally, IDF, 7th edition, 2015.
2. M. K. Ali, K. M. Bullard, J. B. Saaddine, C. C. Cowie, G. Imperatore, E. W. Gregg, "Achievement of goals in U. S. diabetes care, 1999-2010, "The New England Journal ofMedicine, vol. 368, pp. 1613-1624, 2013.
3. US Renal Data System, USRDS 2007 Annual Data Report: Atlas of End-Stage Renal Disease in the United States, National Institutes ofHealth, National Institute of Diabetes andDigestive and Kidney Diseases, Bethesda, Md, USA, 2007.
4. P. Ge, H. Lund-Andersen, H.-H. Parving, O. Pedersen, "Effect of a multifactorial intervention on mortality in type 2 diabetes, "The New England Journal of Medicine, vol. 358, no. 6, pp. 580-591, 2008.
5. C. F. Burant, Ed., Medical Management of Type 2 Diabetes, American Diabetes Association, Alexandria, Va, USA, 7th edition, 2012.
6. H. P. Hansen, E. Tauber-Lassen, B. R. Jensen, H.-H. Parving, "Effect of dietary protein restriction on prognosis in patients with diabetic nephropathy, " Kidney International, vol. 62, no. 1, pp. 220-228, 2002.
7. UK Prospective Diabetes Study (UKPDS) Group, "Intensive blood-glucose controlwith sulphonylureas or insulin compared with conventional treatment and risk of complications in patientswith type 2 diabetes (UKPDS 33), " The Lancet, vol. 352, no. 9131, pp. 837-853, 1998.
8. E. Y. Chew, W. T. Ambrosius, M. D. Davis et al., "ACCORD Study Group; ACCORD Eye Study Group. 'effects of medical therapies on retinopathy progression in type 2 diabetes', " The New England Journal of Medicine, vol. 363, pp. 233-244, 2010.
9. L.-N. Ji, J.-M. Lu, X.-H. Guo et al., "Glycemic control among patients in China with type 2 diabetes mellitus receiving oral drugs or injectables, " BMC Public Health, vol. 13, no. 1, article 602, 2013.
10. A. S. Krolewski, M. A. Niewczas, J. Skupien et al., "Early progressive renal decline precedes the onset of microalbuminuria and its progression to macroalbuminuria, " Diabetes Care, vol. 37, no. 1, pp. 226-234, 2014.
11. T. Scully, "Diabetes in numbers, " Nature, vol. 485, no. 7398, pp. 52-53, 2012.
12. Heart Outcomes Prevention Evaluation Study Investigators, "Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy, " The Lancet, vol. 355, no. 9200, pp. 253-259, 2000.
13. E. J. Lewis, L. G. Hunsicker, W. R. Clarke et al., "Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes, " The New England Journal of Medicine, vol. 345, no. 12, pp. 851-860, 2001.
14. C. J. Pepine, E. M. Handberg, R. M. Cooper-DeHoff et al., "A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease the international Verapamil-Trandolapril study (INVEST): a randomized controlled trial, " Journal of the American Medical Association, vol. 290, no. 21, pp. 2805-2816, 2003.
15. R. Varma, N. M. Bressler, Q. V. Doan et al., "Prevalence of and risk factors for diabetic macular edema in the United States, " JAMA Ophthalmology, vol. 132, no. 11, pp. 1334-1340, 2014.
16. The Diabetic Retinopathy Study Research Group, "Preliminary report on effects of photocoagulation therapy, " American Journal of Ophthalmology, vol. 81, no. 4, pp. 383-396, 1976.
17. Early Treatment Diabetic Retinopathy Study Research Group, "Photocoagulation for diabetic macular edema. Early Treatment Diabetic Retinopathy Study report number 1, " Archives of Ophthalmology, vol. 103, no. 12, pp. 1796-1806, 1985.
18. Q. D. Nguyen, D. M. Brown, D. M. Marcus et al., "Ranibizumab for diabetic macular edema: results from 2 phase III randomized trials: RISE and RIDE, " Ophthalmology, vol. 119, no. 4, pp. 789-801, 2012.
19. The Diabetic Retinopathy Clinical Research Network, "Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema, " The New England Journal of Medicine, vol. 372, no. 13, pp. 1193-1203, 2015.
20. R. Pop-Busui, G. W. Evans, H. C. Gerstein et al., "Effects of cardiac autonomic dysfunction on mortality risk in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial, " Diabetes Care, vol. 33, no. 7, pp. 1578-1584, 2010.
21. V. Spallone, D. Ziegler, R. Freeman et al., "Cardiovascular autonomic neuropathy in diabetes: clinical impact, assessment, diagnosis, management, " Diabetes/Metabolism Research and Reviews, vol. 27, no. 7, pp. 639-653, 2011.
22. A. Sadosky, C. Schaefer, R. Mann et al., "Burden of illness associated with painful diabetic peripheral neuropathy among adults seeking treatment in the US: results from a retrospective chart review and cross-sectional survey, " Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy, vol. 6, pp. 79-92, 2013.
23. C. L. Martin, J. W. Albers, R. Pop-Busui, DCCT/EDIC Research Group, "Neuropathy and related findings in the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications study, " Diabetes Care, vol. 37, no. 1, pp. 31-38, 2014.
24. L. Ang, M. Jaiswal, C. Martin, R. Pop-Busui, "Glucose control and diabetic neuropathy: lessons from recent large clinical trials, " Current Diabetes Reports, vol. 14, no. 9, article 528, pp. 1-15, 2014.
25. S. J. Snedecor, L. Sudharshan, J. C. Cappelleri, A. Sadosky, S. Mehta, M. Botteman, "Systematic review and meta-analysis of pharmacological therapies for painful diabetic peripheral neuropathy, " Pain Practice, vol. 14, no. 2, pp. 167-184, 2014.
26. A. J. M. Boulton, A. I. Vinik, J. C. Arezzo et al., "Diabetic neuropathies: a statement by the American Diabetes Association, " Diabetes Care, vol. 28, no. 4, pp. 956-962, 2005.
27. X.-L. Tong, L. Dong, L. Chen, Z. Zhen, "Treatment of diabetes using traditional Chinese medicine: past, present and future, " American Journal of ChineseMedicine, vol. 40, no. 5, pp. 877-886, 2012.
28. L. Ji, X. Tong, H. Wang et al., "Efficacy and safety of traditional chinese medicine for diabetes: a double-blind, randomised, controlled trial, " PLoSONE, vol. 8, no. 2, Article IDe56703, 2013.
29. X. L. Tong, S. T. Wu, F. M. Lian et al., "The safety and effectiveness of TM81, a Chinese herbal medicine, in the treatment of type 2 diabetes: a randomized double-blind placebo-controlled trial, " Diabetes, Obesity and Metabolism, vol. 15, no. 5, pp. 448-454, 2013.
30. J. Xu, F. Lian, L. Zhao et al., "Structural modulation of gut microbiota during alleviation of type 2 diabetes with a Chinese herbal formula, " ISME Journal, vol. 9, no. 3, pp. 552-562, 2015.
31. A. L. Lee, B. C. Chen, C. H. Mou, M. Sun, H. Yen, "Association of traditional chinese medicine therapy and the risk of vascular complications in patients with type II diabetesmellitus a nationwide, retrospective, taiwanese-registry, cohort study, " Medicine, vol. 95, no. 3, pp. 1-7, 2016.
32. Z. Wang, J. Wang, P. Chan, "Treating type 2 diabetes mellitus with traditional chinese and indian medicinal herbs, " Evidence-Based Complementary and Alternative Medicine, vol. 2013, Article ID 343594, 17 pages, 2013.
33. W. Xie, Y. Zhao, Y. Zhang, "Traditional Chinese medicines in treatment of patients with type 2 diabetes mellitus, " Evidence-Based Complementary and Alternative Medicine, vol. 2011, Article ID 726723, 13 pages, 2011.
34. S.-M. Li, H. Xu, K.-J. Chen, "The diagnostic criteria of blood-stasis syndrome: considerations for standardization of pattern identification, " Chinese Journal of Integrative Medicine, vol. 20, no. 7, pp. 483-489, 2014.
35. J. Yang and M.-Q. Wang, "The research course and the perspective of molecular regulation network and blood stasis syndrome, " Zhongguo Zhong Xi Yi Jie He Za Zhi, vol. 32, no. 10, pp. 1420-1422, 2012.
36. Y.-J. Park, D.-H. Yang, J.-M. Lee, Y.-B. Park, "Development of a valid and reliable blood stasis questionnaire and its relationship to heart rate variability, " ComplementaryTherapies in Medicine, vol. 21, no. 6, pp. 633-640, 2013.
37. C.-H. Lee, T.-C. Li, C.-I. Tsai et al., "Association between albuminuria and different body constitution in type 2 diabetes patients: Taichung diabetic body constitution study, " Evidence-Based Complementary and Alternative Medicine, vol. 2015, Article ID 603048, 8 pages, 2015.
38. J.-S. Wang, H.-J. Yin, K.-J. Chen, "Research progress on mechanism of activating blood circulation to remove stasis treatment for diabetic angiopathy, " Zhongguo Zhong Xi Yi Jie He Za Zhi, vol. 34, no. 11, pp. 1397-1400, 2014.
39. K.-J. Chen, "Blood stasis syndrome and its treatment with activating blood circulation to remove blood stasis therapy, " Chinese Journal of Integrative Medicine, vol. 18, no. 12, pp. 891-896, 2012.
40. X. L. Tong, J. Duan, S. P. Zhou, "Several problems in the diagnosis and treatment of diabetic nephropathy in Chinese and Western Medicine, " China Journal of Traditional Chinese Medicine and Pharmacy, vol. 17, no. 5, pp. 300-303, 2002.
41. S. P. Zhou, X. L. Tong, Y. Xu, "The basic concept and pathological characteristics of collateral disease, " Study Journal of Traditional Chinese Medicine, vol. 20, no. 6, pp. 724-726, 2002.
42. Q. Zhou, Z. Zhen, G. F. Liu, C. Liu et al., "Chinese medicine clinical experience in diabetic nephropathy, " Beijing Journal of Traditional Chinese Medicine, no. 7, pp. 563-565, 2010.
43. M. A. Poliakova and N. A. Gavrilova, "The current conception about the pathogenic mechanisms of the diabetic optical neuropathy development, " Patologicheskaia Fiziologiia I Eksperimental'naia Terapiia, no. 3, pp. 129-132, 2012.
44. X. H. Chen and J. L. Li, "Treatment of diabetic nephropathywith supplementing Qi and activating blood circulation, " Journal of Practical Traditional Chinese InternalMedicine, no. 7, pp. 69-70, 2015.
45. P. Li, Y. P. Chen, J. P. Liu et al., "Efficacy and safety of tangshen formula on patients with type 2 diabetic kidney disease: a multicenter double-blinded randomized placebocontrolled trial, " PLoS ONE, vol. 10, no. 5, Article ID e0126027, 2015.
46. J. X. Tian, L. H. Zhao, Q. Zhou et al., "Retrospective analysis on modifiedDidang Tang for treating microalbuminuria of diabetic nephropathy, " Journal of Beijing University of Traditional Chinese Medicine, no. 6, pp. 7-10, 2012.
47. N. Qing, S. Jiang, Y. X. Xiao et al., "Clinical observation ofQiyao Xiaoke Capsule treating early diabetic nephropathy withmulticenter, randomized, double-blind and placebo control groups, " China Journal of Traditional ChineseMedicine & Pharmacy, vol. 28, no. 8, pp. 2479-2482, 2013.
48. S. T. Ma, D. L. Liu, R. Niu et al., "Tangjiang Shenkang granule in treatment of diabetic nephropathy: a double-blind, randomized, placebo-controlled multi-centre clinical trial, " Chinese Journal of New Drugs & Clinical Remedies, vol. 30, no. 1, pp. 16-19, 2011.
49. B. L. Cao, X. B. Dong, L. F. Yue et al., "Observation on the effect of bushen huayu tangshen fang combined with west medicine in treating 41 cases of Qi-Yin deficiency with bloodstasis syndrome of IV-stage diabetic nephropathy, " Journal of Traditional Chinese Medicine, vol. 56, no. 12, pp. 1043-1046, 2015.
50. W. H. Li andW. H. Ren, "Analysis of clinical eficacy of enalapril combined with tonifying the kidney and promoting blood circulation method on diabetic nephropathy, " Journal of Basic Chinese Medicine, vol. 21, no. 8, pp. 980-982, 2015.
51. F.-L. Wang, Z.-Q. Chen, Y.-H. Wang, "Clinical observation of treating early diabetic nephropathy by qi supplementing, yin nourishing, blood stasis dispersing, collateral dredging recipe, " Chinese Journal of Integrative Medicine, vol. 32, no. 1, pp. 35-38, 2012.
52. M. M. Nentwich and M. W. Ulbig, "Diabetic retinopathy-ocular complications of diabetes mellitus, " World Journal of Diabetes, vol. 6, no. 3, pp. 489-499, 2015.
53. X. C. Liang and S. S. Guo, "The function and effect of Huoxuehuayu in treatment of diabetes and its chronic vascular complications, " Global Traditional Chinese Medicine, vol. 2, no. 2, pp. 118-120, 2009.
54. F. Lian, L. Wu, J. Tian et al., "The effectiveness and safety of a danshen-containing Chinese herbal medicine for diabetic retinopathy: a randomized, double-blind, placebo-controlled multicenter clinical trial, " Journal of Ethnopharmacology, vol. 164, pp. 71-77, 2015.
55. D. Luo, Y. L. Qin, W. Yuan, H. Deng, Y. Zhang, M. Jin, "Compound danshen dripping pill for treating early diabetic retinopathy: a randomized, double-dummy, doubleblind study, " Evidence-Based Complementary and Alternative Medicine, vol. 2015, Article ID 539185, 7 pages, 2015.
56. X.-X. Luo, J.-G. Duan, P.-Z. Liao et al., "Effect of Qiming granule on retinal blood circulation of diabetic retinopathy: amulticenter clinical trial, "Chinese Journal of IntegrativeMedicine, vol. 15, no. 5, pp. 384-388, 2009.
57. L. Feng, W.-K. Liu, L. Deng, J.-X. Tian, X.-L. Tong, "Clinical efficacy of aconitum-containing traditional chinese medicine for diabetic peripheral neuropathic pain, " American Journal of Chinese Medicine, vol. 42, no. 1, pp. 109-117, 2014.
58. Y. Qi and S. J. Yu, "The clinical effect of mudan particles combined with mecobalamine in the treatment of painful diabetic peripheral neuropathy, " World Chinese Medicine, vol. 10, no. 3, pp. 356-358, 2015.
59. T. G. Shang, C. Gao, J. S. Song et al., "Comparison of therapeutic effect ofDanggui SiniDecoction andWesternmedicine in treating peripheral neuropathy in patients with diabetes: a systemic evaluation, " Journal of Tianjin University of Traditional Chinese Medicine, no. 3, 2011.
60. Y. B. Gao, H. Zhou, T. J. Zhang et al., "Clinical research on patients of diabetic peripheral neuropathy treated with Tangluoning, " China Journal of Traditional Chinese Medicine & Pharmacy, vol. 28, no. 6, pp. 1673-1677, 2013.
61. L. La Sala, M. Cattaneo, V. De Nigris et al., "Oscillating glucose induces microRNA-185 and impairs an efficient antioxidant response in human endothelial cells, " Cardiovascular Diabetology, vol. 15, no. 1, p. 71, 2016.
62. X. Zhang, W. Liu, S. Wu, J. Jin, W. Li, N. Wang, "Calcium dobesilate for diabetic retinopathy: a systematic review and meta-analysis, " Science China Life Sciences, vol. 58, no. 1, pp. 101-107, 2014.
63. M. F. Tao and W. D. Yang, "Effects of Xuefu-Zhuyu oral liquid on the auricles microcirculation in mice, " Chinese Journal of Clinical Pharmacology andTherapeutics, no. 1, pp. 89-91, 2003.
64. T. Wang, R. Guo, G. Zhou et al., "Traditional uses, botany, phytochemistry, pharmacology and toxicology of Panax notoginseng (Burk. ) F. H. Chen: a review, " Journal of Ethnopharmacology, vol. 188, pp. 234-258, 2016.
65. G. Liu, G.-J. Guan, T.-G. Qi et al., "Protective effects of Salvia miltiorrhiza on rats with streptozotocin diabetes and its mechanism, " Journal of Chinese Integrative Medicine, vol. 3, no. 6, pp. 459-462, 2005.
66. L. L. Zhang, K. Tian, Z. H. Tang et al., "Phytochemistry and pharmacology of Carthamus tinctorius L, " American Journal of Chinese Medicine, vol. 44, no. 2, pp. 197-226, 2016.
67. L.-G. Yan, J.-S. Ruan, L. Zhang et al., "Effect of aqueous extracts of several kinds of herbs on human platelet aggregation and expression of P-selectin in vitro, " Chinese Journal of Integrative Medicine, vol. 21, no. 4, pp. 286-290, 2015.
68. Y. Fan, Y. Qiao, J. Huang, M. Tang, "Protective effects of Panax notoginseng Saponins against high glucose-induced oxidative injury in rat retinal capillary endothelial cells, " Evidence-Based Complementary and Alternative Medicine, vol. 2016, Article ID 5326382, 9 pages, 2016.
69. D. Q. Yu and H. C. Deng, "Effect of curcumin on glucose and lipid metabolism and oxidative stress in diabetic rats, " Chongqing Medical Journal, vol. 34, no. 1, p. 37, 2005.
70. M. A. Hakim, S. Yang, R. Lai, "Centipede venoms and their components: resources for potential therapeutic applications, " Toxins, vol. 7, no. 11, pp. 4832-4851, 2015.
71. E. J. Henriksen, M. K. Diamond-Stanic, E. M. Marchionne, "Oxidative stress and the etiology of insulin resistance and type 2 diabetes, " Free Radical Biology and Medicine, vol. 51, no. 5, pp. 993-999, 2011.
72. S. M. Li, J. J. Ling, Z. G. Wang, "In-vitro effect of modified Taohe Chengqi Decoction and its separated prescriptions on diabetic angiopathy, " Journal of Guangzhou University of Traditional Chinese Medicine, vol. 25, no. 1, p. 51, 2008.
73. Y. Zhang, J. Wang, L.-L. Guo, G.-J. Wu, "Huoxue anxin recipe alleviated peroxidation damage of acute myocardial infarction rats by regulating iNOS/eNOS imbalance: an experimental research, " Zhongguo Zhong Xi Yi Jie He Za Zhi, vol. 33, no. 10, pp. 1356-1360, 2013.
74. X. X. Qian, Y. Liu, B. Zhou, "To investigate the protective effect and mechanism of Jiawei Buyanghuanwu Decoction on vascular intima of atherosclerotic rabbits, " Chinese Journal of Cardiology, vol. 34, no. 5, pp. 593-594, 2006.
75. C.-L. Liao, L. Tong, Y.-Y. Chen, "Effect of Buyanghuanwu decoction on neuronal nitric oxide synthase expression after permanent focal cerebral ischemia in rats, " Academic Journal of the FirstMedical College of PLA, vol. 24, no. 8, pp. 864-891, 2004.
76. R. P. Garay, P. Hannaert, C. Chiavaroli, "Calcium dobesilate in the treatment of diabetic retinopathy, " Treatments in Endocrinology, vol. 4, no. 4, pp. 221-232, 2005.
77. W. L. Li, H. C. Zheng, J. Bukuru, N. De Kimpe, "Natural medicines used in the traditional Chinese medical system for therapy of diabetesmellitus, " Journal of Ethnopharmacology, vol. 92, no. 1, pp. 1-21, 2004.
78. W. Xie and L. Du, "Diabetes is an inflammatory disease: evidence fromtraditionalChinesemedicines, " Diabetes, Obesity and Metabolism, vol. 13, no. 4, pp. 289-301, 2011.
79. M. Huang, Y. Xie, L. Chen et al., "Antidiabetic effect of the total polyphenolic acids fraction from Salvia miltiorrhiza bunge in diabetic rats, " Phytotherapy Research, vol. 26, no. 6, pp. 944-948, 2012.
80. J. P. Gu, L. Zhao, D. L. Li, "Effect of Hirudo on level of endothelin-1 in diabetic nephyropathy rats, " Chinese Traditional Patent Medicine, vol. 29, no. 10, pp. 1421-1424, 2007.
81. S.-Y. Huang, C. Jeng, S.-C. Kao, J. J.-H. Yu, D.-Z. Liu, "Improved haemorrheological properties by Ginkgo biloba extract (Egb 761) in type 2 diabetes mellitus complicated with retinopathy, " Clinical Nutrition, vol. 23, no. 4, pp. 615-621, 2004.
82. TheDiabetes Control and Complications Trial Research Group, "The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulindependent diabetes mellitus, " The New England Journal of Medicine, vol. 329, no. 14, pp. 977-986, 1993.
83. M. M. Sun, W. W. Liu, Q. Ni, "Research of single herbs in the treatment of Diabetic Peripheral Neuropathy, " Global Traditional Chinese Medicine, vol. 15, no. 4, pp. A1501-A1501, 2013.
84. Y. Liang, S. P. Zhang, C. Q. Deng, "Effect of BuyangHuanwu Decoetion and its basis fractions on arterial thrombosis in mice, " Chinese Journal of Thrombosis & Hemostasis, vol. 11, no. 4, pp. 154-156, 2005.
85. W.-H. You, P. Wang, M.-Q. Li, Y. Zhang, Y.-L. Peng, F.-L. Zhang, "Therapeutic effects of modified Danggui Sini Decoction on plasma level of advanced glycation end products in patients with Wagner grade 0 diabetic foot: a randomized controlled trial, " Journal of Chinese Integrative Medicine, vol. 7, no. 7, pp. 622-628, 2009.
86. L. Ma, "Effect of Huangqi Guizhi Wuwu Decoction on the microcirculation of diabetic peripheral nerve lesion disorder, " Liaoning Journal of Traditional Chinese Medicine, vol. 33, no. 2, pp. 140-141, 2006.
87. S. L. Quan and X. W. Qu, "Effect of Dan Hong Injection on GMP-140 and hemorheology of diabetic patients with vascular disease, " Chinese Journal of Integrative Medicine on Cardio-/Cerebrovascular Disease, vol. 8, no. 11, pp. 1318-1319, 2010.
88. T. Nishikawa and E. Araki, "Impact of mitochondrial ROS production in the pathogenesis of diabetes mellitus and its complications, " Antioxidants&Redox Signaling, vol. 9, no. 3, pp. 343-353, 2007.
89. V. I. Lushchak, "Free radical oxidation of proteins and its relationship with functional state of organisms, " Journal of Biology Chemistry, vol. 72, no. 8, pp. 809-827, 2007.
90. A. Ceriello and E. Motz, "Is oxidative stress the pathogenic mechanism underlying insulin resistance, diabetes, cardiovascular disease The common soil hypothesis revisited, " Arteriosclerosis, Thrombosis, Vascular Biology, vol. 24, no. 5, pp. 816-823, 2004.
91. W. Sun, L. Y. Feng, S. J. Zhao et al., "Study on antioxidant effects and inhibition of podocyte apoptosis of PNS on DN rat, " China Journal of Traditional ChineseMedicine&Pharmacy, vol. 26, no. 5, pp. 1062-1067, 2011.
92. E.-W. Hao, J.-G. Deng, Z.-C. Du et al., "Experimental study on two-way application of traditional Chinese medicines capable of promoting blood circulation and removing blood stasis with neutral property in cold and hot blood stasis syndrome I, " Zhongguo Zhong Yao Za Zhi, vol. 37, no. 21, pp. 3302-3306, 2012.
93. C.-Y. Zhang, J.-J. Zou, Y.-Q. Shi, W. Qu, L.-L. Sun, Z.-M. Liu, "Effect of Tongluo recipe on oxidative stress in kidneys of diabetic rats, " Academic Journal of Second Military Medical University, vol. 29, no. 8, pp. 940-943, 2008.
94. X. J. Bian and X. H. Wang, "Effect of Jiawei Huangqi Guizhi Wuwu Decoction on serum MDA and GSH levels in model rats of diabetic peripheral neuropathy, " Journal of Shandong University of TCM, vol. 34, no. 1, pp. 78-79, 2010.
95. Z. H. Fang and Y. Q. Ni, "Intervention effect of danzhijiangtang capsule on vascular endothelium injury induced by oxidative stress in type two diabetes mellitus, " Journal of Clinical Rational Drug Use, vol. 11, no. 10, p. 5471, 2008.
96. X. L. Tong, S. P. Zhou, A. G. Li, "Efficacy and mechanism of leechon diabetic nephropathy in strptozotocin-induced diabetic rats, " Chinese Journal of Information on TCM, vol. 9, no. 6, pp. 21-23, 2002.
97. Q. S. Peng, "Protective effects of carthamus tinctorius injection on peripheral nerve ischemia-reperfusion injury in rats and its mechanism, " China Pharmacy, vol. 22, no. 23, pp. 2139-2141, 2011.
98. K. Nowotny, T. Jung, A. Hhn, D. Weber, T. Grune, "Advanced glycation end products and oxidative stress in type 2 diabetes mellitus, " Biomolecules, vol. 5, no. 1, pp. 194-222, 2015.
99. C. H. Park, D. H. Kim, M. H. Park et al., "Chinese prescription Kangenkaryu and Salviae miltiorrhizae radix improve agerelated oxidative stress and inflammatory response through the PI3K/Akt or MAPK pathways, " American Journal of Chinese Medicine, vol. 42, no. 4, pp. 987-1005, 2014.
100. D. Montero, G. Walther, C. D. A. Stehouwer, A. J. H. M. Houben, J. A. Beckman, A. Vinet, "Effect of antioxidant vitamin supplementation on endothelial function in type 2 diabetes mellitus: a systematic review and meta-analysis of randomized controlled trials, " Obesity Reviews, vol. 15, no. 2, pp. 107-116, 2014.
101. C. B. Sun, C. Liang, Z. G. Wu et al., "Effects of Tongxinluo on survival of endothelial progenitor cells exposed to advanced glycation end products and the possible mechanism, " Shanghai Medical Journal, vol. 31, no. 10, pp. 711-714, 2008.
102. K. Sun, J. Fan, J. Han, "Ameliorating effects of traditional Chinese medicine preparation, Chinese materia medica and active compounds on ischemia/reperfusion-induced cerebral microcirculatory disturbances and neuron damage, " Acta Pharmaceutica Sinica B, vol. 5, no. 1, pp. 8-24, 2015.
103. S. Bu andW. Y. Yang, "Free fatty acids and lipid toxicity, " Section of Endocrinology ForeignMedical Science, vol. 21, no. 6, pp. 308-310, 2011.
104. B. Shi, W. Y. Yang, X. Wang, "Increased cell apoptosis after 28 weeks of high fat feeding inmale Sprague-Dawley rats, " Chinese Journal of Diabetes, vol. 12, no. 6, pp. 433-436, 2004.
105. T. Meriden, "Progress with thiazolidinediones in the management of type 2 diabetes mellitus, " Clinical Therapeutics, vol. 26, no. 2, pp. 177-190, 2004.
106. C. Gasteyger and A. Tremblay, "Metabolic impact of body fat distribution, " Journal of Endocrinological Investigation, vol. 25, no. 10, pp. 876-883, 2002.
107. D. Tripathy, P. Mohanty, S. Dhindsa et al., "Elevation of free fatty acids induces inflammation and impairs vascular reactivity in healthy subjects, " Diabetes, vol. 52, no. 12, pp. 2882-2887, 2003.
108. Z. L. Zhang, H. L. Li, Y. M. Dong, H. X. Zhao, "Effect of Huoxue Jiangtang Decoction on metabolism and hemorheology in patients with type 2 diabetes mellitus, " Chinese Journal of Basic Medicine in Traditional Chinese Medicine, vol. 10, no. 7, pp. 70-71, 2014.
109. Z. L. Li, H. L. Li, X. Qu, "Effect of Huoxue Jiangtang Yin on type 2 diabetes complications of macrovascular, " China Medicine & Pharmacy, vol. 2, no. 21, pp. 16-18, 2012.
110. X. Guan, F. Huang, J. Z. Wu et al., "Influence of liuweidihuang pills and ginkgo biloca leave to the lipotoxicity and insulin resistance in early time of type 2 diabetes mellitus, " Liaoning Journal of Traditional ChineseMedicine, vol. 33, no. 11, pp. 1423-1426, 2006.
111. Y. Qi and S. J. Yu, "Effect of oxidative stress on Mudan granule lesions of painful diabetic peripheral nerve, " LishizhenMedicine andMateriaMedica Research, vol. 26, no. 7, pp. 1561-1563, 2015.
112. D. W. Laight, M. J. Carrier, E. E. nggard, "Endothelial cell dysfunction and the pathogenesis of diabeticmacroangiopathy, " Diabetes/Metabolism Research and Reviews, vol. 15, no. 4, pp. 274-282, 1999.
113. F. S. Tian, The protective mechanism of clinical and animal experiment study onDaHuang in the vascular disease in diabetes mellitus [M. S. thesis], Hebei Medical University Shijiazhuang China 2007.
114. L. Y. Ma, "The clinical observation on the syndrome differentiation by TCM in the treatment of diabetes, " China Healthy Industry, vol. 10, no. 4, p. 135, 2013.